Yimiao Shenzhou to Present INS21 CAR-T Phase I Clinical Data in Relapsed/Refractory Multiple Myeloma at IMS 2023
Imunopharm
Developer of Gene and Cell Therapy Technologies
In recent years, the research and development of innovative anti-tumor drugs in China has advanced rapidly, gradually achieving a process of evolving from nothing to something, and from weak to strong. An increasing number of domestically produced anti-tumor drugs have made breakthrough progress and achievements, with relevant research data making significant appearances on top international academic platforms, gaining widespread recognition from the global academic community.
On September 13, 2023, Beijing Yimiao Shenzhou Medical Technology Co., Ltd. (hereinafter referred to as "Yimiao Shenzhou" or "the Company") announced,To Be Globally Announced for the First Time in a Presentation at the 20th Annual Meeting of the International Myeloma Society (IMS): INS21, the Self-developed CAR-T Product Based on the InstanCART® Rapid and Efficient Preparation Process PlatformPhase I Clinical Study Data for the Treatment of Relapsed/Refractory Multiple Myeloma (r/r MM). The research data will be orally presented by Professor Liu Hui, Director of the Hematology Department at Beijing Hospital, in the form of a report on September 29 during the Practical Aspects of Immunotherapy session. This is also one of the few presentations at this conference.One of the Two Chinese Myeloma Treatment Research Achievements Selected for the General Session。
The above image is the poster of this report.
It is reported that the 20th Annual Meeting of the International Myeloma Society (IMS), hosted by the International Myeloma Society, will be held in Athens, Greece, from September 27 to 30, 2023. The conference is dedicated to promoting the latest groundbreaking scientific and clinical exchanges in multiple myeloma and related plasma cell disorders. The IMS Annual Meeting has successfully been held for 19 sessions and stands as the premier academic event in the field of international myeloma.It is reported that this year, China has 2 research papers selected for the General Session, 4 research papers selected for the Oral Abstract Session, and 34 research papers selected for the Poster session.
He TingPh.D.
Founder & CEO of Yimiao Shenzhou
CEO of Beijing Yimiaoshenzhou Medical Techology Co., Ltd., Dr. He TingRepresentation: We are very pleased to present the latest Phase I clinical research data of INS21 for the treatment of relapsed/refractory multiple myeloma (r/r MM) in an oral report at the IMS Annual Meeting. We also look forward to contributing "Chinese wisdom" to the advancement of global multiple myeloma treatment. Although CAR-T therapy has demonstrated remarkable efficacy in treating r/r MM, the short treatment window for patients, combined with the long production cycle and high costs of traditional CAR-T manufacturing, significantly reduces patient accessibility. INS21, however, utilizes the company's proprietary InstanCART® rapid and efficient platform technology, which substantially reduces production time, effectively lowering manufacturing costs and patient waiting times. This is of great significance for improving patient accessibility and the applicability of CAR-T products.
Previously, Beijing Yimiaoshenzhou Medical Technology Co., Ltd. presented clinical trial data of INS21 CAR-T for the treatment of relapsed or refractory multiple myeloma (r/r MM) at the 64th ASH Annual Meeting in 2022, drawing significant attention from the industry. Subsequently, due to its groundbreaking and revolutionary potential in treating r/r MM, the product won the top prize in the finals of the 2022 China Disruptive Technology Innovation Competition and was selected for the "Top 100 New Technologies and Products List" at the 2023 Zhongguancun Forum International Technology Trade Conference.
About INS21
INS21 is the first self-developed CAR-T product by Beijing Yimiaoshenzhou Medical Technology Co., Ltd. that utilizes the InstanCART rapid and efficient preparation process. It overcomes the technical challenges of traditional autologous CAR-T cell production, such as long production cycles, high costs, complex procedures, and low accessibility, successfully reducing the production time of autologous CAR-T cells from the industry standard of 2 to 6 weeks to just two days. The product has demonstrated good safety, efficacy, and anti-tumor efficiency in clinical studies, effectively enhancing clinical outcomes, reducing production costs, and improving patient accessibility. Once on the market, it will benefit more patients with advanced multiple myeloma.
// About Yimiao Shenzhou //
Yimiao Shenzhou, established in 2015 with its headquarters in Beijing, is a leading innovative pharmaceutical company at the clinical stage. With the mission of "making cancer no longer an incurable disease," it focuses on applying cutting-edge gene and cell drug technologies to treat major diseases (such as cancer and autoimmune diseases). To date, the company has completed 9 rounds of strategic financing and owns a one-stop independent gene and cell drug R&D and industrialization platform, mastering multiple core technologies. It has won the top prize in the finals of China’s Disruptive Technology Innovation Competition and obtained four clinical trial approvals for Class I new drugs as well as Beijing's first Drug Manufacturing License for gene and cell therapy drugs. Its R&D pipeline covers hematological malignancies such as lymphoma, leukemia, and myeloma, as well as solid tumors like liver cancer, colorectal cancer, gastric cancer, and pancreatic cancer, making it a leader in the field of gene and cell therapy drugs.
The company has undertaken more than 10 national and provincial-level scientific research projects, such as the special project of the Ministry of Science and Technology's key R&D plan and Beijing's major science and technology special project. It is a national high-tech enterprise, a Beijing specialized, refined, distinctive, and innovative enterprise, a Zhongguancun Frontier Technology Enterprise, a Zhongguancun High-tech Enterprise, and a postdoctoral research workstation. The team has been honored with awards such as Beijing Science and Technology Nova, Zhongguancun High-end Leading Talent, Beijing Haiying Talent, Xinguomen Leading Talent, the Gold Award (First Place) in Tsinghua University President’s Cup Innovation Challenge, MIT Technology Review's 35 Innovators Under 35, and Fortune magazine's 40 Under 40 Business Elites.
